Patients with corticosteroid-dependent recurrent pericarditis may exhibit varying responses to different IL-1 blocking agents.
Varying IL-1 blocker responses in recurrent pericarditis warrant caution against class equivalence; leaves open optimal agent selection for confirmation in trials.
Recurrent pericarditis (RP) has a controversial pathogenesis that crosses infectious, auto-immune and auto-inflammatory pathways. It has been suggested that in some cases it might be an unrecognized auto-inflammatory disease. Recent studies have demonstrated that anakinra, an interleukin-1 receptor antagonist (IL-1RA), represents an effective treatment for the control of corticosteroid-dependent cases.
No takes yet. Share an insight, caveat, or question.
Theodoropoulou et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: